Testicular vein thrombosis: Incidence of recurrent venous thromboembolism and survival.

Autor: Lenz CJ; Division of Vascular Cardiology, Mayo Clinic, Rochester, MN, USA., McBane RD; Division of Vascular Cardiology, Mayo Clinic, Rochester, MN, USA., Cohoon KP; Division of Vascular Cardiology, Mayo Clinic, Rochester, MN, USA., Janczak DT; Division of Oncology and Palliative Care, Faculty of Health Science, Wroclaw Medical University, Wroclaw, Poland., Simmons BS; Division of Vascular Cardiology, Mayo Clinic, Rochester, MN, USA., Saadiq RA; Division of Vascular Cardiology, Mayo Clinic, Rochester, MN, USA., Mimier M; Department and Clinic of Ophthalmology, Wroclaw Medical University, Wroclaw, Poland., Casanegra AI; Division of Vascular Cardiology, Mayo Clinic, Rochester, MN, USA., Daniels PR; Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA., Wysokinski WE; Division of Vascular Cardiology, Mayo Clinic, Rochester, MN, USA.
Jazyk: angličtina
Zdroj: European journal of haematology [Eur J Haematol] 2018 Jan; Vol. 100 (1), pp. 83-87. Date of Electronic Publication: 2017 Nov 13.
DOI: 10.1111/ejh.12985
Abstrakt: Purpose: Testicular vein thrombosis (TVT) etiology, recurrence, and survival were compared with lower extremity deep vein thrombosis (DVT) in order to determine whether treatment guidelines for DVT could be applied to TVT.
Patients and Methods: An inception cohort of patients with confirmed TVT (January 1995-October 2015) was compared to a control group of patients with lower extremity DVT matched by age, gender, and diagnosis date.
Results: Thirty-nine men with TVT were identified; 15 (38%) with isolated TVT. Left testicular vein was affected in 77% patients; there were no cases of bilateral TVT. Cancer was over twofold more common in TVT patients (59% vs 28%, P = .01). Most cancers (78%) involved organs in proximity to the testicular vein. Although TVT patients were less frequently treated with anticoagulants (49% vs 97%, P = .0001), recurrence rates were similar to DVT group (TVT 4.2 vs DVT 1.1 per 100 patient-years, P = .11). Despite higher cancer prevalence, survival rates were similar between groups (31% vs 28%; P = .34). Major bleeding events were rare (one patient per group).
Conclusions: Identifying TVT should prompt a search for a regional malignancy. Despite the high cancer prevalence and low utilization of anticoagulants, recurrent venous thrombosis and mortality rates are similar to DVT patients.
(© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje